$ELVN
Enliven Therapeutics, Inc. Stock $elvn

$elvn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024031495 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.017M	$4.824M	$18.96M
YoY Change	32.53%	56.62%	23.65%
% of Gross Profit
Research & Development	$19.97M	$17.91M	$64.57M
YoY Change	68.1%	9847.22%	240.94%
% of Gross Profit
Depreciation & Amortization	$79.00K	$78.00K	$297.0K
YoY Change	-99.88%		-50.5%
% of Gross Profit
Operating Expenses	$25.99M	$22.73M	$83.53M
YoY Change	58.28%	597.21%	143.74%
Operating Profit	-$25.99M		-$83.53M
YoY Change	58.28%		-11542.33%
Interest Expense	$3.250M	$3.368M	$11.97M
YoY Change	91.85%	560.39%	1169.03%
% of Operating Profit
Other Income/Expense, Net	$3.249M	-$9.000K	-$22.00K
YoY Change	91.79%	-145.0%	-102.6%
Pretax Income	-$22.74M	-$19.37M	-$71.58M
YoY Change	54.47%	-160.02%	-4642.13%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$22.74M	-$19.37M	-$71.58M
YoY Change	54.43%	-160.17%	-4910.75%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.54		-$2.01
Diluted Earnings Per Share	-$0.54	-$0.47	-$2.01
COMMON SHARES
Basic Shares Outstanding	41.35M	41.21M	35.55M
Diluted Shares Outstanding	42.05M		35.55M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$320.5M	$253.1M	$253.1M
YoY Change	9.72%	187.02%	235.12%
Cash & Equivalents	$149.2M	$100.1M	$100.1M
Short-Term Investments	$171.3M	$153.0M	$153.0M
Other Short-Term Assets	$16.70M	$13.00M	$13.00M
YoY Change	182.97%	491.05%	485.72%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$337.2M	$266.2M	$266.2M
YoY Change	13.15%	196.92%	242.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$683.0K	$1.062M	$1.062M
YoY Change	-19.93%	19.33%	-30.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.091M	$4.654M	$4.654M
YoY Change	20.15%	100.34%	15.48%
Total Long-Term Assets	$5.578M	$5.716M	$5.716M
YoY Change	14.7%	146.06%	2.99%
TOTAL ASSETS
Total Short-Term Assets	$337.2M	$266.2M	$266.2M
Total Long-Term Assets	$5.578M	$5.716M	$5.716M
Total Assets	$342.8M	$271.9M	$271.9M
YoY Change	13.18%	195.64%	226.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.727M	$532.0K	$532.0K
YoY Change	-53.46%	257.05%	-82.95%
Accrued Expenses	$12.30M	$15.36M	$15.36M
YoY Change	141.25%	813.86%	132.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.03M	$25.89M	$25.89M
YoY Change	128.76%	1314.97%	166.4%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$34.00K	$67.00K	$67.00K
YoY Change	-93.31%	-89.83%	-89.85%
Total Long-Term Liabilities	$34.00K	$67.00K	$67.00K
YoY Change	-93.31%	-89.83%	-89.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.03M	$25.89M	$25.89M
Total Long-Term Liabilities	$34.00K	$67.00K	$67.00K
Total Liabilities	$25.07M	$25.96M	$25.96M
YoY Change	118.91%	1318.63%	150.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$177.2M	-$154.4M
YoY Change	81.56%	5.75%
Common Stock	$47.00K	$41.00K
YoY Change	-99.97%	51.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$317.7M	$245.9M	$245.9M
YoY Change
Total Liabilities & Shareholders Equity	$342.8M	$271.9M	$271.9M
YoY Change	13.18%	195.64%	226.37%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$22.74M	-$19.37M	-$71.58M
YoY Change	54.43%	-160.17%	-4910.75%
Depreciation, Depletion And Amortization	$79.00K	$78.00K	$297.0K
YoY Change	-99.88%		-50.5%
Cash From Operating Activities	-$23.36M	-$12.48M	-$61.27M
YoY Change	12.08%	563.94%	72.26%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$14.00K	$149.0K
YoY Change	-33.33%		-58.61%
Acquisitions
YoY Change
Other Investing Activities	-$17.87M	$38.70M	-$148.3M
YoY Change		-7.46%	-292.85%
Cash From Investing Activities	-$17.89M	$38.69M	-$148.4M
YoY Change	57593.55%	-7.49%	-293.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$399.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	90.27M	90.00K	234.3M
YoY Change	-61.98%	-107.32%	-19101.3%
NET CHANGE
Cash From Operating Activities	-23.36M	-12.48M	-61.27M
Cash From Investing Activities	-17.89M	38.69M	-148.4M
Cash From Financing Activities	90.27M	90.00K	234.3M
Net Change In Cash	49.02M	26.29M	24.61M
YoY Change	-77.36%	-32.07%	-38.04%
FREE CASH FLOW
Cash From Operating Activities	-$23.36M	-$12.48M	-$61.27M
Capital Expenditures	$20.00K	$14.00K	$149.0K
Free Cash Flow	-$23.38M	-$12.50M	-$61.42M
YoY Change	12.01%	564.68%	70.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001672619
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201912Member
CY2023	elvn	Lease Commencement Date LeaseCommencementDate	2022-07-31
CY2023Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://www.enliventherapeutics.com/20231231#AccruedExpensesAndOtherCurrentLiabilities
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39247
CY2023	dei	Entity Registrant Name EntityRegistrantName	ENLIVEN THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1523849
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	6200 Lookout Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boulder
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80301
CY2023	dei	City Area Code CityAreaCode	720
CY2023	dei	Local Phone Number LocalPhoneNumber	647-8519
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	ELVN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	382300000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41347632
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	San Francisco, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100141000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75536000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	153007000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	54000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2949000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2217000
CY2023Q4	elvn	Contingent Value Right Asset ContingentValueRightAsset	10000000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	266151000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	77753000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	742000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	890000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	320000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	626000
CY2023Q4	elvn	Deferred Offering Costs Non Current DeferredOfferingCostsNonCurrent	563000
CY2022Q4	elvn	Deferred Offering Costs Non Current DeferredOfferingCostsNonCurrent	3975000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	54000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4091000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2023Q4	us-gaap	Assets Assets	271867000
CY2022Q4	us-gaap	Assets Assets	83298000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	532000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3438000
CY2023Q4	elvn	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	15362000
CY2022Q4	elvn	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	6277000
CY2023Q4	elvn	Contingent Value Right Liability ContingentValueRightLiability	10000000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25894000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9715000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	67000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	659000
CY2023Q4	us-gaap	Liabilities Liabilities	25961000
CY2022Q4	us-gaap	Liabilities Liabilities	10374000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	26264364
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41292027
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41292027
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3570019
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3570019
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	41000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400172000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6038000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	141000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154448000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82864000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	245906000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-76825000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	271867000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83298000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64574000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31022000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18955000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7769000
CY2023	us-gaap	Operating Expenses OperatingExpenses	83529000
CY2022	us-gaap	Operating Expenses OperatingExpenses	38791000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-83529000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-38791000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	11967000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1129000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11945000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1129000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71584000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37662000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	141000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71443000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37662000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.05
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35546215
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35546215
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3124274
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3124274
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-42887000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	246000
CY2022	elvn	Vesting Of Restricted Stock And Stock Options VestingOfRestrictedStockAndStockOptions	287000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3191000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37662000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-76825000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	475000
CY2023	elvn	Vesting Of Restricted Stock And Stock Options VestingOfRestrictedStockAndStockOptions	295000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	149749000
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4955000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	159544000
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	80241000
CY2023	elvn	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	9044000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12914000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71584000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	141000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	245906000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71584000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37662000
CY2023	us-gaap	Depreciation Depreciation	297000
CY2022	us-gaap	Depreciation Depreciation	215000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	12914000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3191000
CY2023	elvn	Non Cash Lease Expense NonCashLeaseExpense	306000
CY2022	elvn	Non Cash Lease Expense NonCashLeaseExpense	0
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4603000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0
CY2023	elvn	Write Off Of Deferred Ipo Costs WriteOffOfDeferredIPOCosts	0
CY2022	elvn	Write Off Of Deferred Ipo Costs WriteOffOfDeferredIPOCosts	1741000
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	3703000
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1590000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-310000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2250000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	411000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7664000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1613000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61269000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32077000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	120000000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	268263000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	149000
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	612000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-148412000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-612000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	399000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	591000
CY2022	elvn	Payment Of Deferred Offering Costs Related To The Merger And Initial Public Offering PaymentOfDeferredOfferingCostsRelatedToTheMergerAndInitialPublicOffering	2390000
CY2023	elvn	Payment Of Deferred Offering Costs Related To The Sales Agreement PaymentOfDeferredOfferingCostsRelatedToTheSalesAgreement	563000
CY2022	elvn	Payment Of Deferred Offering Costs Related To The Sales Agreement PaymentOfDeferredOfferingCostsRelatedToTheSalesAgreement	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	161365000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	elvn	Proceeds From Cash Acquired In Connection With Reverse Recapitalization ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization	81821000
CY2022	elvn	Proceeds From Cash Acquired In Connection With Reverse Recapitalization ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization	0
CY2023	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	8736000
CY2022	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	234286000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1799000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	24605000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34488000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75590000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110078000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100195000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75590000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100141000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75536000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	54000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	54000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100195000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75590000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	387000
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	149749000
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0
CY2023	elvn	Deferred Offering Costs Related To The Merger Included In Accounts Payable And Accrued Expenses And Other Current Liabilities DeferredOfferingCostsRelatedToTheMergerIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities	0
CY2022	elvn	Deferred Offering Costs Related To The Merger Included In Accounts Payable And Accrued Expenses And Other Current Liabilities DeferredOfferingCostsRelatedToTheMergerIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities	1846000
CY2023	elvn	Receivables From Stock Option Exercises Included In Prepaid Expenses And Other Current Assets ReceivablesFromStockOptionExercisesIncludedInPrepaidExpensesAndOtherCurrentAssets	76000
CY2022	elvn	Receivables From Stock Option Exercises Included In Prepaid Expenses And Other Current Assets ReceivablesFromStockOptionExercisesIncludedInPrepaidExpensesAndOtherCurrentAssets	0
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2019-06-12
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-4
CY2023Q1	elvn	Business Acquisition Exchange Ratio BusinessAcquisitionExchangeRatio	0.002951
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41011501
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41011501
CY2023Q1	elvn	Business Acquisition Exchange Ratio BusinessAcquisitionExchangeRatio	0.002951
CY2023Q1	elvn	Majority Number Of Initial Members Of Board Of Directors MajorityNumberOfInitialMembersOfBoardOfDirectors	8
CY2023Q1	elvn	Business Acquisition Exchange Ratio BusinessAcquisitionExchangeRatio	0.002951
CY2023Q1	elvn	Contigent Value Rights For Each Outstanding Shares ContigentValueRightsForEachOutstandingShares	one
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	164500000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154400000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	253100000
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.574%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Certain prior period balances have been reclassified to conform to current period presentation of the Company’s consolidated financial statements and accompanying notes. Such reclassifications have no effect on previously reported results of operations, accumulated deficit, subtotals of operating, investing or financing cash flows or consolidated balance sheet totals. For the year ended December 31, 2022, the Company reclassified $</span><span style="font-size:10pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> million of deferred offering costs included in accrued liabilities and $</span><span style="font-size:10pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> million of deferred offering costs included in accounts payable within the supplemental disclosure of non-cash investing and financial activities in the consolidated statements of cash flows.</span></p>
CY2022	elvn	Deferred Offering Costs Included In Accrued Liabilities DeferredOfferingCostsIncludedInAccruedLiabilities	1200000
CY2022	elvn	Deferred Offering Costs Included In Accounts Payable DeferredOfferingCostsIncludedInAccountsPayable	600000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.574%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to stock-based compensation and accrued research and development expenses. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. Actual results may differ from those estimates or assumptions.</span></p>
CY2023	elvn	Restricted Cash Collateral Of Sublease RestrictedCashCollateralOfSublease	54000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	54000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	54000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.574%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities, as well as restricted cash. The Company maintains deposits in U.S. federally insured financial institutions in excess of federally insured limits. The Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity. Although management currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. As of December 31, 2023</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, the Company has not experienced any losses in its accounts and believes it is not exposed to significant credit risk on its cash balances.</span></p>
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Adopted ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted	true
CY2023Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Adoption Date ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate	2022-01-01
CY2023Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Immaterial Effect ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect	true
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	81821000
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	1044000
CY2023Q1	elvn	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities	2624000
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	80241000
CY2023Q1	elvn	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	9000000
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5000000
CY2023Q4	elvn	Deferred Offering Costs Related To Merger And Financing Transaction DeferredOfferingCostsRelatedToMergerAndFinancingTransaction	0
CY2022Q4	elvn	Deferred Offering Costs Related To Merger And Financing Transaction DeferredOfferingCostsRelatedToMergerAndFinancingTransaction	4000000
CY2023Q1	elvn	Fair Value Assessment Of Payments Under Contingent Value Rights Agreement FairValueAssessmentOfPaymentsUnderContingentValueRightsAgreement	0
CY2023Q4	elvn	Contingent Value Rights Agreement Asset ContingentValueRightsAgreementAsset	10000000
CY2023Q4	elvn	Contingent Value Rights Agreement Liability ContingentValueRightsAgreementLiability	10000000
CY2023	elvn	Payments Received Under Contingent Value Rights Agreement PaymentsReceivedUnderContingentValueRightsAgreement	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	152866000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	147000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	153007000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	0
CY2020Q2	elvn	Area Of Leased Office And Laboratory Space AreaOfLeasedOfficeAndLaboratorySpace	6782
CY2020Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2021-12-30
CY2021Q1	elvn	Area Of Leased Office Space AreaOfLeasedOfficeSpace	2495
CY2021Q1	elvn	Area Of Leased Office Space AreaOfLeasedOfficeSpace	9277
CY2021Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	12000
CY2022Q2	elvn	Lessee Operating Lease Extended Date LesseeOperatingLeaseExtendedDate	2024-12-30
CY2023Q4	elvn	Area Of Leased Office Space AreaOfLeasedOfficeSpace	18170
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P1Y
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	4
CY2023Q4	elvn	Operating Lease Remaining Right Of Use Asset OperatingLeaseRemainingRightOfUseAsset	300000
CY2023Q4	elvn	Operating Remaining Lease Liability OperatingRemainingLeaseLiability	300000
CY2022Q4	elvn	Operating Lease Remaining Right Of Use Asset OperatingLeaseRemainingRightOfUseAsset	600000
CY2022Q4	elvn	Operating Remaining Lease Liability OperatingRemainingLeaseLiability	600000
CY2023	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	400000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	300000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	341000
CY2023Q4	elvn	Lessee Operating Lease Liability Payments Due After Year One LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	341000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	335000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	335000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1413000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1264000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	671000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	374000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	742000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	890000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3328000
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2130000
CY2023Q4	elvn	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	10433000
CY2022Q4	elvn	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	1918000
CY2023Q4	elvn	Accrued Deferred Offering Cost Current AccruedDeferredOfferingCostCurrent	0
CY2022Q4	elvn	Accrued Deferred Offering Cost Current AccruedDeferredOfferingCostCurrent	1190000
CY2023Q4	elvn	Lease Liability Current LeaseLiabilityCurrent	335000
CY2022Q4	elvn	Lease Liability Current LeaseLiabilityCurrent	323000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	902000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	269000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	364000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	447000
CY2023Q4	elvn	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	15362000
CY2022Q4	elvn	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	6277000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41292027
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41292027
CY2023Q4	elvn	Common Stock Number Of Shares Subject To Repurchase CommonStockNumberOfSharesSubjectToRepurchase	86153
CY2022Q4	elvn	Common Stock Number Of Shares Subject To Repurchase CommonStockNumberOfSharesSubjectToRepurchase	252652
CY2023Q4	elvn	Common Stock Liability Related To Shares Subject To Repurchase CommonStockLiabilityRelatedToSharesSubjectToRepurchase	400000
CY2022Q4	elvn	Common Stock Liability Related To Shares Subject To Repurchase CommonStockLiabilityRelatedToSharesSubjectToRepurchase	600000
CY2023Q4	elvn	Number Of Vote By Common Stock Holders NumberOfVoteByCommonStockHolders	1
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	34426351
CY2023Q1	elvn	Business Acquisition Exchange Ratio BusinessAcquisitionExchangeRatio	0.002951
CY2023Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	18216847
CY2023Q1	elvn	Pre Merger Financing Amount PreMergerFinancingAmount	164500000
CY2023Q1	elvn	Pre Merger Financing Shares Issued PreMergerFinancingSharesIssued	12638636
CY2023Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	0
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	18216847
CY2023	elvn	Stock Issued During Period Shares Upon Exercise Of Stock Options Outstanding StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding	5817339
CY2022	elvn	Stock Issued During Period Shares Upon Exercise Of Stock Options Outstanding StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding	3316671
CY2023Q4	elvn	Issuance Of Common Stock Upon Vesting Of Restricted Stock Units IssuanceOfCommonStockUponVestingOfRestrictedStockUnits	78505
CY2022Q4	elvn	Issuance Of Common Stock Upon Vesting Of Restricted Stock Units IssuanceOfCommonStockUponVestingOfRestrictedStockUnits	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1574426
CY2022	elvn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercised In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisedInPeriodTotalIntrinsicValue	100000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.62
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	906265
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7873027
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	22439783
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3075403
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.64
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9657000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	391653
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.66
CY2022	elvn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriod	-141462
CY2022	elvn	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised And Vested In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice	3.72
CY2022	elvn	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelledInPeriod	-8923
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.68
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3316671
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.2
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1194000
CY2023	elvn	Share Based Compensation Arrangement By Share Based Payment Award Assumption Of Options In Connection With Merger ShareBasedCompensationArrangementByShareBasedPaymentAwardAssumptionOfOptionsInConnectionWithMerger	449900
CY2023	elvn	Share Based Compensation Arrangements By Share Based Payment Award Assumption Of Options In Connection With Merger Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardAssumptionOfOptionsInConnectionWithMergerWeightedAverageExercisePrice	28.4
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2563778
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.65
CY2023	elvn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriod	-316194
CY2023	elvn	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised And Vested In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice	2.42
CY2023	elvn	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelledInPeriod	-196816
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.32
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5817339
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.9
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	35692000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2457579
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.41
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	24169000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5817339
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.9
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	35692000
CY2023	elvn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercised In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisedInPeriodTotalIntrinsicValue	4500000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4
CY2022Q4	elvn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	180000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42931000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19775000
CY2023Q4	elvn	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	1370000
CY2022Q4	elvn	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	243000
CY2023Q4	elvn	Deferred Tax Assets Accruals And Other Expenses Not Currently Deductible DeferredTaxAssetsAccrualsAndOtherExpensesNotCurrentlyDeductible	834000
CY2022Q4	elvn	Deferred Tax Assets Accruals And Other Expenses Not Currently Deductible DeferredTaxAssetsAccrualsAndOtherExpensesNotCurrentlyDeductible	594000
CY2023Q4	elvn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	94000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12914000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3191000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.053
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.067
CY2023	elvn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.003
CY2022	elvn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.015
CY2023	elvn	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	0.015
CY2022	elvn	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.26
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.267
CY2023	elvn	Effective Income Tax Rate Reconciliation Adjustment Of Tax Credits And Reversal EffectiveIncomeTaxRateReconciliationAdjustmentOfTaxCreditsAndReversal	-0.012
CY2022	elvn	Effective Income Tax Rate Reconciliation Adjustment Of Tax Credits And Reversal EffectiveIncomeTaxRateReconciliationAdjustmentOfTaxCreditsAndReversal	-0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	40000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	43000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19745000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12894000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1535000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	399000
CY2023Q4	elvn	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	19313000
CY2022Q4	elvn	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	5422000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	55000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	49000
CY2023Q4	elvn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	90000
CY2022Q4	elvn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	175000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	145000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	224000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42786000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19551000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	23200000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10100000
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The 2017 Tax Cuts and Jobs Act (“TCJA”) generally allows losses incurred after 2017 to be carried over indefinitely but limits the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation’s taxable income (subject to IRC Section 382). Additionally, there is no carryback for losses incurred after 2017. Losses incurred prior to 2018 are generally deductible to the extent of the lesser of a corporation’s net operating loss carryover or 100% of its taxable income and are available for twenty years from the period the loss was generated.
CY2023Q4	elvn	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	177300000
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	200000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	164000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	47000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	28698000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	7000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3282000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	110000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32144000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	164000
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	89000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	45000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71584000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37662000
CY2023	elvn	Weighted Average Common Shares Outstanding WeightedAverageCommonSharesOutstanding	35702864
CY2022	elvn	Weighted Average Common Shares Outstanding WeightedAverageCommonSharesOutstanding	3548829
CY2023	elvn	Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions	119154
CY2022	elvn	Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions	194966
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	37495
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	229589
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35546215
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35546215
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3124274
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3124274
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.05
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5908578
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21625471
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0000950170-24-031495-index-headers.html	Edgar Link	pending
0000950170-24-031495-index.html	Edgar Link	pending
0000950170-24-031495.txt	Edgar Link	pending
0000950170-24-031495-xbrl.zip	Edgar Link	pending
elvn-20231231.htm	Edgar Link	pending
elvn-20231231.xsd	Edgar Link	pending
elvn-ex10_10.htm	Edgar Link	pending
elvn-ex10_11.htm	Edgar Link	pending
elvn-ex10_12.htm	Edgar Link	pending
elvn-ex10_13.htm	Edgar Link	pending
elvn-ex10_14.htm	Edgar Link	pending
elvn-ex10_15.htm	Edgar Link	pending
elvn-ex10_16.htm	Edgar Link	pending
elvn-ex10_3.htm	Edgar Link	pending
elvn-ex10_6.htm	Edgar Link	pending
elvn-ex10_7.htm	Edgar Link	pending
elvn-ex10_8.htm	Edgar Link	pending
elvn-ex10_9.htm	Edgar Link	pending
elvn-ex21_1.htm	Edgar Link	pending
elvn-ex23_1.htm	Edgar Link	pending
elvn-ex31_1.htm	Edgar Link	pending
elvn-ex31_2.htm	Edgar Link	pending
elvn-ex32_1.htm	Edgar Link	pending
elvn-ex32_2.htm	Edgar Link	pending
elvn-ex4_2.htm	Edgar Link	pending
elvn-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img251772460_0.jpg	Edgar Link	pending
img251772460_1.jpg	Edgar Link	pending
img251772460_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
elvn-20231231_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELVN
Enliven Therapeutics, Inc. Stock $elvn

2024 Q1 Form 10-K Financial Statement

#000095017024031495 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELVN Enliven Therapeutics, Inc. Stock $elvn

2024 Q1 Form 10-K Financial Statement

#000095017024031495 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELVN
Enliven Therapeutics, Inc. Stock $elvn